Nintedanib is an oral angiokinase inhibitor used as second-line treatment for non–small cell lung cancer. New radiotracers, such as ⁶⁸Ga-DOTA-E-[c(RGDfK)]², that target α_vβ₃ integrin might have an impact as a noninvasive method for assessing angiogenesis inhibitors. Methods: From July 2011 through October 2015, 38 patients received second-line nintedanib plus docetaxel. All patients underwent PET/CT with ⁶⁸Ga-DOTA-E-[c(RGDfK)]² radiotracer and blood-sample tests to quantify angiogenesis factors (fibroblast growth factor, vascular endothelial growth factor, and platelet-derived growth factor AB) before and after completing 2 therapy cycles. Results: Of the 38 patients, 31 had available baseline and follow-up PET/CT. Baseline lung tumor volume addressed with ⁶⁸Ga-DOTA-E-[c(RGDfK)]² PET/CT correlated with serum vascular endothelial growth factor levels, whereas baseline lung/liver SUV_max index correlated with platelet-derived growth factor AB. After treatment, the overall response rate and disease control rate were 7.9% and 47.3%, respectively. A greater decrease in lung tumor volume (−37.2% vs. –27.6%) was associated with a better disease control rate in patients (P = 0.005). Median progression-free survival was 3.7 mo. Nonsmokers and patients with a higher baseline lung tumor volume were more likely to have a higher progression-free survival (6.4 vs. 3.74 [P = 0.023] and 6.4 vs. 2.1 [P = 0.003], respectively). Overall survival was not reached. Patients with a greater decrease in lung SUV_max (not reached vs. 7.1 mo; P = 0.016) and a greater decrease in the lung/spleen SUV_max index (not reached vs. 7.1; P = 0.043) were more likely to have a longer overall survival. Conclusion: ⁶⁸Ga-DOTA-E-[c(RGDfK)]² PET/CT is a potentially useful tool for assessing responses to angiogenesis inhibitors. Further analysis and novel studies are warranted to identify patients who might benefit from this therapy.

Nintedanib是一种口服血管激酶抑制剂，用于非小细胞肺癌的二线治疗。新放射性示踪剂，如⁶⁸ Ga的DOTA-E- [C（RGDfK）] ²，即目标α _v β ₃整联可能具有作为评估血管生成抑制剂的非侵入性方法的影响。方法： 2011年7月至2015年10月，38例患者接受二线nintedanib加多西他赛治疗。所有患者在接受PET / CT之前均接受⁶⁸ Ga-DOTA-E- [c（RGDfK）] ²放射性示踪剂和血液样本测试，以量化血管生成因子（成纤维细胞生长因子，血管内皮生长因子和血小板衍生生长因子AB）完成2个治疗周期后。结果： 38例患者中，有31例具有基线和随访PET / CT。用⁶⁸ Ga-DOTA-E- [c（RGDfK）] ² PET / CT处理的基线肺肿瘤体积与血清血管内皮生长因子水平相关，而基线肺/肝脏SUV _max指数与血小板衍生生长因子AB相关。治疗后，总缓解率和疾病控制率分别为7.9％和47.3％。肺肿瘤体积的更大减少（−37.2％比–27.6％）与患者更好的疾病控制率相关（P = 0.005）。中位无进展生存期为3.7个月。非吸烟者和基线肺肿瘤量更高的患者更有可能获得更高的无进展生存期（6.4 vs. 3.74 [P = 0.023]和6.4对2.1 [ P = 0.003]。未达到总生存期。肺SUV _max降低幅度更大（未达到7.1 mo，P = 0.016）并且肺/脾SUV _max指数降低幅度更大（未达到7.1；P = 0.043）的患者更有可能患上SUV 。总体生存期更长。结论： ⁶⁸ Ga-DOTA-E- [c（RGDfK）] ² PET / CT是评估血管生成抑制剂反应的潜在有用工具。有必要进行进一步的分析和新颖的研究，以鉴定可能从这种治疗中受益的患者。